UK-based manufacturer unveils revolutionary liquid sickle cell treatment
UK-based pharmaceutical manufacturer Nova Laboratories has unveiled details of its new liquid formulation of hydroxycarbamide at the Annual Sickle Cell and Thalassaemia conference in...
Janssen announces new Stelara® data for ulcerative colitis
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new two-year data from the long-term extension of the Phase 3 UNIFI study, demonstrating...
MHRA senior appointments
The Medicines and Healthcare products Regulatory Agency (MHRA) is welcoming two directors. The MHRA senior appointments have now taken up their posts. Graeme Tunbridge has...
Consumers at risk of buying fake pharmaceutical products
60% of online search results for pharmaceutical drug leads to fakes putting consumers at risk of buying fake pharmaceutical products. Google and other search engines...
Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate on atrial fibrillation diagnosis
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive...
Contracts awarded to deliver urgent medicines after Brexit
The Government has awarded contracts to deliver urgent medicines after Brexit. Three companies have been awarded the contracts for express freight service to deliver...
Licence secured for first UK medicinal cannabis distribution centre
Spectrum Therapeutics has secured licences for the first UK medicinal cannabis distribution centre. Spectrum Therapeutics UK received licences from the UK Medicines and Healthcare products...
Shareholders approve proposed acquisition of Allergan by AbbVie
Following the June announcement of the proposed acquisition of Allergan by Abbvie, Allergan has announced that its shareholders have voted to approve the proposed...
Medicines Bill could improve access to new dementia treatments
The Government has announced new legislation aimed at providing faster access to medicines. The Medicines and Medical Devices Bill, announced in the Queen’s Speech...
Clovis Oncology’s ovarian cancer treatment approved for Cancer Drugs Fund
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund...
Latest articles
Mind the Generation Gap in pharma marketing and market research
Industry came together to explore the impact of the generation gap in pharma marketing and market research at BHBIA's summer event. Different generations have always...
AstraZeneca presents anifrolumab results from Phase III TULIP trial
Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...
Popular articles
NHS Commercial Framework for Medicines consultation published
NHS England has published the NHS Commercial Framework for Medicines for consultation. NHS England has a significant role to play in supporting patient access to...
Mapping NHS change is key to customer engagement
Simon Grime, of Wilmington Healthcare, explains how mapping NHS change through data and intelligence can help industry understand and engage customers in the new...
Pf Power List 2019: Who is shaping the pharma & healthcare sector?
The Pf Power List has looked at who is making a difference in pharma and healthcare in 2019. This year has brought a range of developments...
Medopad and Janssen collaborate on novel digital biomarker for Alzheimer’s disease
Medopad has announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and...
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...